Skip to main content

Year in review · from our August 2026 register copy

NAFDAC registrations in 2023

By the approval dates our August 2026 copy of the Greenbook records, 2,293 products were approved onto the register in 2023 — 1,779 of them in Drugs. 100% of the class of 2023 is still active in our copy today.

By category

Month by month

Approvals are batched — quiet months and spikes are the register's own rhythm, not demand.

Jan
105
Feb
181
Mar
102
Apr
249
May
195
Jun
27
Jul
390
Aug
133
Sep
156
Oct
104
Nov
272
Dec
379

Who registered the most

  1. 1.Novartis Nigeria49 approvals
  2. 2.Phillips Pharmaceuticals (Nigeria)43 approvals
  3. 3.Emzor Pharmaceutical Industries41 approvals
  4. 4.Krishat Pharma Industries36 approvals
  5. 5.Drugfield Pharmaceuticals32 approvals
  6. 6.Geneith Pharmaceuticals30 approvals
  7. 7.Bioraj Pharmaceuticals29 approvals
  8. 8.Ranbaxy Nigeria28 approvals
  9. 9.Alben Health Care Industries26 approvals
  10. 10.Roche Products26 approvals

Where the year's medicines were made

Factory countries recorded on 1,777 of the year's 1,779 drug approvals.

Month-to-month changes — new listings, renewals, lapses — live on the NAFDAC Registry Watch, updated with every register refresh.

Other years

Counted from the approval dates in our dated copy of the public NAFDAC Greenbook. The register backfills approval entries long after the fact, so a year's count can still grow after it ends — which is also why the current year has no page until it completes. Registration counts are not market share or sales.